
Innate Pharma Reports Full Year 2019 Financial Results and Business Update
Innate globally expands its capital markets presence with a successful NASDAQ IPO and Global Offering that provided gross proceeds of $79.1 million (€71.5 million1) Monalizumab to advance to a Phase III clinical trial in combination with cetuximab in IO- …